Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Clinical trial NCT01682083 · COMPLETED
Trial details
- NCT number
- NCT01682083
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-08
- Primary completion
- 2017-06-30
- Enrollment
- 870
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.